The legislation involves a public hearing to discuss proposed ordinances related to a partial settlement of lawsuits against major opioid distributors and manufacturers, seeking abatement funds totaling between $33 million and $61 million over several years. This hearing is scheduled for November 2, 2021, at 3:00 p.m.
Hearing of the Board of Supervisors sitting as a Committee of the Whole on November 2, 2021, at 3:00 p.m., to hold a public hearing to consider the proposed Ordinances (File Nos. 211071 and 211072) regarding existing litigation relating to the partial settlement of the lawsuit filed on behalf of the City and County of San Francisco and the People of the State of California against three large distributors of prescription opioids (AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation) for abatement funds in the range of $27 million to $50 million to be paid over 18 years, entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; and the partial settlement of the lawsuit filed on behalf of the City and County of San Francisco and the People of the State of California against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., for abatement funds in the range of $6 million to $11 million to be paid over nine years, entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; scheduled pursuant to Motion Nos. M21-148 (File No. 211112) and M21-149 (File No. 211114), approved on October 26, 2021.
How it got here
This legislation originated from ongoing litigation against major opioid distributors and manufacturers, prompting the Board of Supervisors to hold a public hearing on proposed ordinances related to partial settlements.
The Board approved Motion Nos. M21-148 and M21-149, which scheduled a public hearing regarding existing litigation related to opioid distributors and manufacturers.
The Board of Supervisors held a public hearing to consider proposed ordinances regarding the partial settlement of lawsuits against opioid distributors and Johnson & Johnson.
Reconstructed from attached documents & the official record
The ordinance authorizes a partial settlement of a lawsuit against three major opioid distributors, aiming to secure between $27 million and $50 million in abatement funds over 18 years. This lawsuit alleges that these companies contributed to the opioid crisis in San Francisco by distributing excessive amounts of opioids while ignoring legal obligations to monitor and report suspicious orders.
The ordinance authorizes a partial settlement of a lawsuit against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, for $6 million to $11 million over nine years due to their role in the opioid crisis. The lawsuit alleges that they created a public nuisance and violated laws through deceptive marketing and distribution of opioids in San Francisco.
The motion endorses a settlement of a lawsuit against major distributors of prescription opioids, which the City and County of San Francisco filed. It also schedules a public hearing and a closed session for the Board of Supervisors to discuss the litigation with the City Attorney.
The motion endorses a settlement in a lawsuit against major distributors of prescription opioids, aimed at addressing the opioid crisis in San Francisco. It also schedules a public hearing and a closed session for the Board of Supervisors to discuss the litigation with the City Attorney.
This legislation allows the San Francisco Board of Supervisors to hold a closed session to discuss legal advice regarding ongoing lawsuits against major opioid distributors and manufacturers, seeking settlement funds for the city. The lawsuits aim to secure between $27 million to $50 million and $6 million to $11 million in abatement funds to address the opioid crisis over specified timeframes.
The ordinance authorizes a partial settlement of a lawsuit against three major opioid distributors, aiming to secure between $27 million and $50 million in abatement funds over 18 years. This lawsuit alleges that these companies contributed to the opioid crisis in San Francisco by distributing excessive amounts of opioids while ignoring legal obligations to monitor and report suspicious orders.
The ordinance authorizes a partial settlement of a lawsuit against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, for $6 million to $11 million over nine years due to their role in the opioid crisis. The lawsuit alleges that they created a public nuisance and violated laws through deceptive marketing and distribution of opioids in San Francisco.
This legislation allows the San Francisco Board of Supervisors to hold a closed session to discuss legal advice regarding ongoing lawsuits against major opioid distributors and manufacturers, seeking settlement funds for the city. The lawsuits aim to secure between $27 million to $50 million and $6 million to $11 million in abatement funds to address the opioid crisis over specified timeframes.
The motion endorses a settlement of a lawsuit against major distributors of prescription opioids, which the City and County of San Francisco filed. It also schedules a public hearing and a closed session for the Board of Supervisors to discuss the litigation with the City Attorney.
The motion endorses a settlement in a lawsuit against major distributors of prescription opioids, aimed at addressing the opioid crisis in San Francisco. It also schedules a public hearing and a closed session for the Board of Supervisors to discuss the litigation with the City Attorney.